Literature DB >> 14582910

Substance P-induced pulmonary vascular remodelling in precision cut lung slices.

J Springer1, A Fischer.   

Abstract

Substance P (SP) levels have been reported to be elevated in animal models of pulmonary hypertension (PH) and chronic administration of SP has been shown to induce PH. In the present study, the role of reactive oxygen species (ROS) as mediators of SP-induced vascular remodelling and PH was analysed. Vascular remodelling was induced in precision cut lung slices by treatment with [Sar9,Met11(O2)]-SP and by hypoxia. Functional analyses were used to study the chronic [Sar9,Met11(O2)]-SP-mediated effects on proliferation and generation of ROS, which is involved in the pathogenesis of PH. The nonpeptide NK-1 receptor antagonist CP 96345 was used to block [Sar9,Met11(O2)]-SP effects. ROS generation and proliferation was assayed by the dichloroflourescein-diacetate method and incorporation of 5-Bromo-2'-Deoxyuridine, respectively. ROS generation was induced by either 1% oxygen (5.8-fold) or [Sar9,Met11(O2)]-SP (8-fold) in normoxia in the alveolar region. [Sar9,Met11(O2)]-SP did not further elevate ROS levels in hypoxia, suggesting an oxygen-dependent mechanism. High ROS levels stabilised hypoxia inducible factor-1alpha and induced proliferation in small vessels (4.3-fold in hypoxia and [Sar9,Met11(O2)]-SP). Both ROS generation and proliferation were blocked in the presence of CP 96345, nitroblue-tetrazolium, N-acetylcysteine- and diphenylene-iodonium. The results presented in this study indicate a role of SP in proliferative events associated with vascular remodelling in pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14582910     DOI: 10.1183/09031936.03.00027903

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia.

Authors:  Edward C Dempsey; Marilee J Wick; Vijaya Karoor; Erica J Barr; Dustin W Tallman; Carol A Wehling; Sandra J Walchak; Sven Laudi; Mysan Le; Masahiko Oka; Susan Majka; Carlyne D Cool; Karen A Fagan; Dwight J Klemm; Louis B Hersh; Norma P Gerard; Craig Gerard; York E Miller
Journal:  Am J Pathol       Date:  2009-03       Impact factor: 4.307

2.  S-nitrosothiols signal hypoxia-mimetic vascular pathology.

Authors:  Lisa A Palmer; Allan Doctor; Preeti Chhabra; Mary Lynn Sheram; Victor E Laubach; Molly Z Karlinsey; Michael S Forbes; Timothy Macdonald; Benjamin Gaston
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

3.  Hypoxic vasoconstriction of partial muscular intra-acinar pulmonary arteries in murine precision cut lung slices.

Authors:  Renate Paddenberg; Peter König; Petra Faulhammer; Anna Goldenberg; Uwe Pfeil; Wolfgang Kummer
Journal:  Respir Res       Date:  2006-06-29

4.  Increased S100A4 expression in the vasculature of human COPD lungs and murine model of smoke-induced emphysema.

Authors:  Sebastian Reimann; Ludger Fink; Jochen Wilhelm; Julia Hoffmann; Mariola Bednorz; Michael Seimetz; Isabel Dessureault; Roger Troesser; Bahil Ghanim; Walter Klepetko; Werner Seeger; Norbert Weissmann; Grazyna Kwapiszewska
Journal:  Respir Res       Date:  2015-10-20

Review 5.  The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension.

Authors:  Charmaine C W Lo; Seyed M Moosavi; Kristen J Bubb
Journal:  Front Physiol       Date:  2018-08-23       Impact factor: 4.566

Review 6.  Repurposing of medications for pulmonary arterial hypertension.

Authors:  Mark Toshner; Edda Spiekerkoetter; Harm Bogaard; Georg Hansmann; Sylvia Nikkho; Kurt W Prins
Journal:  Pulm Circ       Date:  2020-11-18       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.